InnoCare Pharma Ltd. ( (HK:9969) ) has shared an update.

InnoCare Pharma announced that its Phase III registrational trial of fadeucravacitinib (ICP‑488) in adults with moderate‑to‑severe plaque psoriasis met its primary endpoint with statistically significant and clinically meaningful improvement versus placebo. The randomized, double‑blind, placebo‑controlled, multicenter study also achieved multiple secondary efficacy endpoints, and the safety profile was consistent with earlier trials with no new safety signals identified.

Given the high costs, injection burden and long‑term safety concerns associated with existing biologic therapies for psoriasis, the positive Phase III results highlight the potential of fadeucravacitinib as an effective oral alternative offering durable disease control. InnoCare plans to complete long‑term safety follow‑up and advance regulatory filings for ICP‑488 in psoriasis, a move that could strengthen its position in the autoimmune therapeutics market, though the company cautions there is no assurance the drug will ultimately be successfully commercialized.

The most recent analyst rating on (HK:9969) stock is a Buy
with a HK$17.00 price target.
To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock,
see the HK:9969 Stock Forecast page.